ALK-Abelló

Board/Management Information • May 31, 2012

Copenhagen, 2012-05-31 08:50 CEST (GLOBE NEWSWIRE) --

ALK announces the appointment of Søren Daniel Niegel (40 years) as new
Executive Vice President (International Sales and Marketing) and member of the
Board of Management of ALK-Abelló A/S.

Søren Daniel Niegel will be responsible for International Marketing and ALK’s
affiliates in Europe, China and the USA.

Søren Daniel Niegel holds a M.Sc. in Economics and Business Administration from
Copenhagen Business School. He joins ALK from a position as Vice President
Strategic Operations Europe at Novo Nordisk. From his many different positions
at Novo Nordisk in Denmark, the Netherlands, France and Switzerland, Søren
Daniel Niegel has gained significant management and business experience.

Søren Daniel Niegel will start at ALK on 1 August 2012.

                             ALK-Abelló A/S


                               Jens Bager
                            President and CEO

Contact person: Jens Bager, President and CEO, tel. +45 4574 7576

About ALK
ALK is a research-driven global pharmaceutical company focusing on allergy
prevention, diagnosis and treatment. ALK is the world leader in allergy
immunotherapy – a unique treatment of the underlying cause of allergy. The
company has approximately 1,800 employees with subsidiaries, production
facilities and distributors worldwide. ALK has entered into partnership
agreements with Merck and Torii to commercialise allergy immunotherapy tablets
in North America and Japan, respectively. The company is headquartered in
Hørsholm, Denmark, and listed on the NASDAQ OMX Copenhagen A/S. Find more
information at www.alk-abello.com.